Re:Guillain-Barré Syndrome After Covid-19 Vaccination in US ...
by neogodless on Thursday December 09, 2021 @04:14PM
(#29503026)
The short summary of what this paper describes is an increase in GBS specific to the Johnson & Johnson vaccine (Ad.26.COV2.S), with no significant change for recipients of mRNA vaccines.
> The incidence of GBS in the 21 days after Ad.26.COV2.S was 34.6 per 100,000 person-years, which was substantially greater than the expected background rate of 1-2 per 100,000 person-years.
> The incidence of GBS in the 21 days after Ad.26.COV2.S was 34.6 per 100,000 person-years, which was substantially greater than the expected background rate of 1-2 per 100,000 person-years.